相关临床试验
17
11 进行中
药物批准
3
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
11
64.7%
已完成
4
23.5%
Unknown
2
11.8%
- X-Chem and Orion Pharma have expanded their strategic collaboration from hit identification to candidate selection, leveraging DNA-encoded library technology and AI-driven approaches for multiple early-stage programs. - The new Technology Access Agreement enables Orion to utilize X-Chem's integrated discovery capabilities, including DEL screening, AI-driven hit triage, and medicinal chemistry support to advance small molecule discovery. - This partnership combines X-Chem's ArtemisAI platform with computational and medicinal chemistry expertise to help partners make informed decisions earlier in the discovery process, reducing risk and improving outcomes.
- Bayer received FDA approval for Nubeqa (darolutamide) in combination with docetaxel chemotherapy for metastatic hormone-sensitive prostate cancer, expanding beyond its initial non-metastatic indication. - The ARASENS trial demonstrated a 33% reduction in death risk when Nubeqa was added to standard androgen deprivation therapy plus docetaxel compared to placebo. - Bayer has tripled its peak sales forecast for Nubeqa from €1 billion to €3 billion following positive clinical data in the metastatic setting. - The approval positions Nubeqa to compete directly with established androgen receptor inhibitors Xtandi and Erleada in the advanced prostate cancer market.
- Finnish researchers have developed an ML-powered tool called HASTEN that reduces virtual drug screening time from 6 months to under 10 days for 1.56 billion molecules. - The system successfully identified 90% of top-scoring drug candidates when screening just 1% of the compound library against bacterial and viral targets. - Orion Pharma and University of Eastern Finland researchers have made their datasets public to advance computational drug discovery research.
